Replimune Group, Inc. is a biotechnology company focused on developing oncolytic immunotherapies aimed at treating various difficult-to-treat cancers. The company operates a proprietary RPx platform and conducts multiple clinical trials to explore its applications in oncology. Replimune also has a manufacturing facility in the U.S. to support global supply for its therapies. Its mission is to activate tumor-specific immune responses to improve cancer treatment outcomes for patients.
